ANI Pharmaceuticals, Inc. (ANIP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in ANI Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

ANI Pharmaceuticals, Inc. (ANIP) has returned -2.58% so far this year and 14.86% over the past 12 months. Over the last ten years, ANIP has returned 8.52% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since May 5, 2000, ANIP's average daily return is +0.10%, while the average monthly return is +1.58%. At this rate, your investment would double in approximately 3.7 years.

Historically, 50% of months were positive and 50% were negative. The best month was Apr 2001 with a return of +151.3%, while the worst month was Dec 2011 at -79.1%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ANIP closed higher 45% of trading days. The best single day was Jun 2, 2000 with a return of +78.6%, while the worst single day was Dec 15, 2011 at -77.4%.

ANI Pharmaceuticals, Inc. has an annualized alpha of 20.27%, beta of 0.85, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since May 08, 2000.

• This stock participated in 145.81% of S&P 500 Index downside but only 110.89% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ANIP ranks 52 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for ANI Pharmaceuticals, Inc. (ANIP) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the ANI Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ANI Pharmaceuticals, Inc. was 98.81%, occurring on Jun 25, 2013. The portfolio has not yet recovered.

The current ANI Pharmaceuticals, Inc. drawdown is 82.91%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of ANI Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how ANI Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.